Press Releases - 2011
Medic Vision Receives FDA Clearance for its SafeCT System
Jan. 4, 2011
The New SafeCTTM Offers Highly Diagnostic Low-Dose Imaging Capabilities to the Thousands of CT Scanners Left with No Recourse to Dose Reduction.
Haifa, Israel, January 5, 2011—Medic Vision Ltd., a company specializing in medical imaging solutions, announced today that it has received clearance from the U.S. Food and Drug Administration to market its SafeCT product in the USA. The SafeCT, recently unveiled at the 2010 RSNA meeting, processes and enhances images spanning a broad range of clinical applications acquired on a wide variety of CT scanners. SafeCT enables a dramatic 50% dose reduction in CT scans without compromising image quality and diagnostic information.
Recent health concerns over CT radiation in diagnostic imaging have given rise to dedicated dose reduction features in a limited number of new CT scanner models. Over 10,000 CT scanners are currently in use in the USA alone—with an estimated 30,000 worldwide—the majority of which are left without a suitable dose-reduction solution. SafeCT, which is compatible with most major CT platforms and PACS, can provide low-dose imaging functionality to these scanners, ensuring safe and efficacious CT scanning.
“Based on unique proprietary and patented image reconstruction technology, SafeCT offers a ready universal add-on solution, ideal for hospitals and private imaging centers alike,” commented Ezer Bar-Aviv, CTO of Medic Vision. “A single SafeCT system can provide robust low-dose imaging functionality to any number of CT scanners in a radiology department.”
SafeCT has been clinically validated at leading medical centers, with hundreds of patients tested and results presented in a number of papers. “The SafeCT-processed low-dose images strongly and consistently demonstrate equivalence or even preferential image and diagnostic quality when compared to the standard dose studies,” stated Emanuel Kanal, MD, Professor of Radiology and Director of MR Services at the University of Pittsburgh Medical Center, in his presentation at the ASNR 2010 annual meeting.
“Our company is focused primarily on materializing the huge potential of our SafeCT product in the the U.S. market. We are currently exploring strategic partnerships to facilitate the distribution of our CT dose-reduction system to American clinicians and to promote synergetic collaborations for integrating our system into existing and emerging CT scanner platforms,” indicated Eyal Aharon, CEO of Medic Vision.
Left: standard-dose image at 396 mAs, 140 kVp; right: SafeCT-reconstructed image of a registered 198 mAs, 120 kVp study of the same patient, showing similar image quality at less than 50% dose level.
About Medic Vision
Established in 2006 and based in Haifa, Israel, Medic Vision specializes in medical imaging solutions. Medic Vision's sophisticated proprietary algorithms technology for fast and precise image reconstruction provides the platform on which its products are based. These solutions are universal, making them ideal for direct end-user applications as well as for incorporation by CT and PACS manufacturers into their existing platforms/product offerings.
For further information visit our website: www.medicvision.com, or contact:
Eyal Aharon at +972-54-8004500 or firstname.lastname@example.org.